Company news
BriaCell Therapeutics Corp news in 2026
BriaCell Therapeutics Corp's news releases, calls and decks from 2026, newest first.
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
November 6, 2026
BriaCell Awarded 2026 "Immunotherapy Solution of the Year" By BioTech Breakthrough
November 5, 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
November 3, 2026
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
October 23, 2026
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
October 6, 2026
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
September 14, 2026
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
September 8, 2026
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+(TM)
August 24, 2026
BriaCell Receives FDA Clearance to Initiate Bria-PROS+(TM) Clinical Study in Prostate Cancer
August 5, 2026
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
July 16, 2026
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
July 15, 2026
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
July 7, 2026
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)
June 25, 2026
BriaCell Therapeutics Announces Closing of Offering
June 2, 2026
BriaCell Presents Positive Clinical Data at ASCO 2026
June 1, 2026
BriaCell Therapeutics Announces Pricing of Offering
May 31, 2026
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
May 22, 2026
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+
May 18, 2026
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+(TM)
May 15, 2026
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+(TM) for Prostate Cancer
May 14, 2026
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
May 13, 2026
BriaCell Phase 3 Bria-IMT(TM) Study Enrollment Surpasses 230 Patients
May 12, 2026
BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
May 7, 2026
BriaCell Receives FDA Clearance to Initiate Bria-BRES+(TM) Clinical Study in Breast Cancer
May 6, 2026
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
April 27, 2026
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) in Preclinical Cancer Models
April 21, 2026
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
April 20, 2026
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
March 31, 2026
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
March 18, 2026
BriaCell to Present Positive Clinical Data for Bria-IMT(TM) and Preclinical Data for Next Generation Bria-OTS+(TM) Personalized Immunotherapy at the 2026 AACR Conference
March 18, 2026
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
March 10, 2026
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
March 5, 2026
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
February 18, 2026
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
January 28, 2026
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
January 27, 2026
BriaCell Therapeutics Announces Closing of US$30 million Public Offering
January 15, 2026
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
January 13, 2026
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
January 13, 2026
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
January 7, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 27 slides · Sep 28, 2026